Export 37 results:
Author Title Type [ Year(Desc)]
Filters: Author is Hill, Heather  [Clear All Filters]
F. M. Munoz, Weisman, L. E., Read, J. S., Siberry, G., Kotloff, K., Friedman, J., Higgins, R. D., Hill, H., Seifert, H., and Nesin, M., Assessment of safety in newborns of mothers participating in clinical trials of vaccines administered during pregnancy., Clin Infect Dis, vol. 59 Suppl 7, pp. S415-27, 2014.
K. L. Kotloff, Halasa, N. B., Harrison, C. J., Englund, J. A., Walter, E. B., King, J. C., C Creech, B., Healy, S. A., Dolor, R. J., Stephens, I., Edwards, K. M., Noah, D. L., Hill, H., and Wolff, M., Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children., Pediatr Infect Dis J, vol. 33, no. 8, pp. 865-71, 2014.
R. L. Atmar, Opekun, A. R., Gilger, M. A., Estes, M. K., Crawford, S. E., Neill, F. H., Ramani, S., Hill, H., Ferreira, J., and Graham, D. Y., Determination of the 50% human infectious dose for Norwalk virus., J Infect Dis, vol. 209, no. 7, pp. 1016-22, 2014.
D. I. Bernstein, Jackson, L., Patel, S. M., Sahly, H. M. El, Spearman, P., Rouphael, N., Rudge, T. L., Hill, H., and Goll, J. B., Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults., Vaccine, vol. 32, no. 47, pp. 6284-93, 2014.
R. B. Belshe, Frey, S. E., Graham, I. L., Anderson, E. L., Jackson, L. A., Spearman, P., Edupuganti, S., Mulligan, M. J., Rouphael, N., Winokur, P., Dolor, R. J., Woods, C. W., Walter, E. B., Chen, W. H., Turley, C., Edwards, K. M., C Creech, B., Hill, H., and Bellamy, A. R., Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial., JAMA, vol. 312, no. 14, pp. 1420-8, 2014.
S. E. Frey, Winokur, P. L., Hill, H., Goll, J. B., Chaplin, P., and Belshe, R. B., Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals., Vaccine, vol. 32, no. 23, pp. 2732-9, 2014.
M. J. Mulligan, Bernstein, D. I., Winokur, P., Rupp, R., Anderson, E., Rouphael, N., Dickey, M., Stapleton, J. T., Edupuganti, S., Spearman, P., Ince, D., Noah, D. L., Hill, H., and Bellamy, A. R., Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial., JAMA, vol. 312, no. 14, pp. 1409-19, 2014.
S. E. Frey, Wald, A., Edupuganti, S., Jackson, L. A., Stapleton, J. T., Sahly, H. El, El-Kamary, S. S., Edwards, K., Keyserling, H., Winokur, P., Keitel, W., Hill, H., Goll, J. B., Anderson, E. L., Graham, I. L., Johnston, C., Mulligan, M., Rouphael, N., Atmar, R., Patel, S., Chen, W., Kotloff, K., C Creech, B., Chaplin, P., and Belshe, R. B., Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects., Vaccine, vol. 33, no. 39, pp. 5225-34, 2015.
L. A. Jackson, Campbell, J. D., Frey, S. E., Edwards, K. M., Keitel, W. A., Kotloff, K. L., Berry, A. A., Graham, I., Atmar, R. L., C Creech, B., Thomsen, I. P., Patel, S. M., Gutierrez, A. F., Anderson, E. L., Sahly, H. M. El, Hill, H., Noah, D. L., and Bellamy, A. R., Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial., JAMA, vol. 314, no. 3, pp. 237-46, 2015.
S. E. Frey, Bernstein, D. I., Brady, R. C., Keitel, W. A., Sahly, H. El, Rouphael, N. Georges, Mulligan, M. J., Atmar, R. L., Edupuganti, S., Patel, S. M., Dickey, M., Graham, I., Anderson, E. L., Noah, D. L., Hill, H., Wolff, M., and Belshe, R. B., Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations., Vaccine, vol. 33, no. 1, pp. 163-73, 2015.
N. B. Halasa, Gerber, M. A., Berry, A. A., Anderson, E. L., Winokur, P., Keyserling, H., Eckard, A. Ross, Hill, H., Wolff, M. C., McNeal, M. M., Edwards, K. M., and Bernstein, D. I., Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age., J Pediatric Infect Dis Soc, vol. 4, no. 3, pp. 214-24, 2015.